BioNTech Clocks Over $6B In Q1 Sales, Sticks To FY22 Guidance
See more from Benzinga
FDA Limits Use of Johnson & Johnson's COVID-19 Vaccine to Certain Individuals - All You Should Know
Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.